These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17217313)

  • 1. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
    Huse DM; von Mehren M; Lenhart G; Joensuu H; Blanke C; Feng W; Finkelstein S; Demetri G
    Clin Drug Investig; 2007; 27(2):85-93. PubMed ID: 17217313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
    Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
    J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
    Hislop J; Quayyum Z; Elders A; Fraser C; Jenkinson D; Mowatt G; Sharma P; Vale L; Petty R
    Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.
    Dretzke J; Round J; Connock M; Tubeuf S; Pennant M; Fry-Smith A; Hulme C; McCabe C; Meads C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):63-70. PubMed ID: 21047493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
    Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
    Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study).
    Mabasa VH; Taylor SC; Chu CC; Moravan V; Johnston K; Peacock S; Knowling M
    J Oncol Pharm Pract; 2008 Sep; 14(3):105-12. PubMed ID: 18524863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
    Contreras-Hernández I; Mould-Quevedo JF; Silva A; Salinas-Escudero G; Villasís-Keever MA; Granados-García V; Dávila-Loaiza G; Petersen JA; Garduño-Espinosa J
    Br J Cancer; 2008 Jun; 98(11):1762-8. PubMed ID: 18506179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
    Zuidema S; Desar IME; van Erp NP; Kievit W
    Br J Clin Pharmacol; 2019 Sep; 85(9):1994-2001. PubMed ID: 31112617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
    Dalziel K; Round A; Garside R; Stein K
    Pharmacoeconomics; 2005; 23(5):515-26. PubMed ID: 15896102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors.
    Banerjee S; Kumar A; Lopez N; Zhao B; Tang CM; Yebra M; Yoon H; Murphy JD; Sicklick JK
    JAMA Netw Open; 2020 Sep; 3(9):e2013565. PubMed ID: 32986105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour.
    Chabot I; LeLorier J; Blackstein ME
    Eur J Cancer; 2008 May; 44(7):972-7. PubMed ID: 18372169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib: a review of its use in the management of gastrointestinal stromal tumours.
    Siddiqui MA; Scott LJ
    Drugs; 2007; 67(5):805-20. PubMed ID: 17385949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors.
    Rutkowski P; Gronchi A
    Oncologist; 2013 Jun; 18(6):689-96. PubMed ID: 23709752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.